Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update

Clinical, News,

Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography…

Read more

Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA

News,

Telix is delighted to announce the appointment of Gabrielle Wermenbol as Chief Financial Officer, Europe, Middle East and Africa…

Read more

Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations

News,

Telix is pleased to announce that Ms. Kyahn Williamson has joined the Telix executive leadership team in the role of Senior Vice President of Corporate Communications and Investor…

Read more

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Clinical, News,

Telix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder…

Read more

IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update

Clinical, News,

Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line…

Read more

Telix Update on FDA New Drug Application Review for Illuccix®

ASX, News,

Telix announces participation in a late-cycle meeting with the U.S. FDA regarding the ongoing review of the NDA for its prostate cancer imaging investigational product…

Read more

Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

Events, News,

Telix is pleased to announce the launch of TelixU, a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied…

Read more

Scott Law joins Telix as SVP Global Manufacturing Operations

News,

Telix is delighted to announce that Scott Law has joined the Company as Senior Vice President, Global Manufacturing…

Read more

Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy

ASX, News,

Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA…

Read more

Telix Symposium at SNMMI 2021 Virtual Annual Meeting

Events, News,

Telix is pleased to announce we will be presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Virtual Annual Meeting to be held 11 – 15…

Read more
1 … 30 31 32 33 34 … 46

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings